INTRODUCTION

Worldwide, more than 240 million people are living with chronic liver infections, and about 600,000 people die every year due to the acute or chronic consequences of hepatitis B virus (HBV) infections [1]. HBV infection is a major cause of acute and chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC), as well as a factor contributing to death from liver disease in Korea [2,3].

Most Korean chronic hepatitis B (CHB) patients are...
infected with the HBV subgenotype C2, which is known to have a lower hepatitis B e-antigen seroconversion rate, more rapid progression to cirrhosis and HCC, a lower interferon treatment response rate, and a higher relapse rate after antiviral treatment, compared with other HBV genotypes [4,5].

Entecavir (ETV) is a cyclopentyl guanosine analog with potent selective inhibition of the priming, DNA-dependent synthesis and reverse transcription functions of the HBV polymerase. Clinical studies have shown it to be a potent, safe, and tolerable antiviral agent, and it is recommended as first-line monotherapy for patients with compensated or decompensated CHB [6]. In real-world cohort studies of more than 1,000 patients treated with ETV for up to 6 years, ETV has shown long-term effectiveness, as well as low rates for development of resistance, and a good safety profile [7]. But, most studies were performed in single or small number of institutes or have limitation in patient’s number.

We conducted a large-scale, nation-wide surveillance study in accordance with the Korean Ministry of Food and Drug Safety’s protocol for reexamination of new drugs postapproval. The study included 3,444 CHB patients, and was conducted to identify occurrence of all adverse events (AEs), including unexpected adverse drug events and serious adverse events (SAEs) regardless of any causal relationship to the study drug, as well as the factors related to the safety and efficacy of ETV. Furthermore, we investigated all AEs, including unexpected and rare AEs, which had no established relationship with ETV treatment, and proposed alternative explanations for their occurrence, based on closely monitoring these AEs.

Here we report data from this study with regard to the safety and clinical effectiveness of ETV treatment in Korean patients with CHB including liver cirrhosis.

METHODS

This surveillance study was conducted prospectively in accordance with a protocol approved by the Korean Ministry of Food and Drug Safety (MFDS). Each institution participating in this study received Institutional Review Board (IRB) review for the research approval (for example, IRB no. of Uijeongbu St. Mary’s Hospital UCMCo8MPo07). Written informed consent was obtained from each patient at the time of enrollment.

Patients

A total of 3,444 patients were enrolled between May 2006 and May 2012 from 132 Korean institutions. Of these, 39 patients were excluded because they were enrolled prior to contract execution with the institutions, 20 patients had duplicate enrollments, 14 patients were lost to follow-up, three patients had off-label use, and one patient was not administrated the study drug, leaving 3,367 patients for safety evaluation. Among these 3,367 patients, 238 were treated for fewer than 16 weeks, and efficacy or clinical effectiveness could not be assessed for a further 14 patients; therefore, 3,115 patients were evaluated for efficacy and clinical effectiveness (Fig. 1).

Data collection

The mean treatment duration was 258.34 ± 151.49 days (median, 204). Two hundred and thirty-one patients (6.88%) were treated for less than 16 weeks, 793 patients (23.61%) for ‘16 weeks or more and less than 24 weeks’ and 2,335 patients (69.51%) for more than 24 weeks. During the study period, reported AEs were presented in accordance with the 2010 World Health Organization Adverse Reaction Terminology criteria, with System Organ Class and Preferred Term. For the safety evaluation, an AE was defined as any event that was not present at the onset of ETV therapy.

Efficacy was evaluated by measuring a change in aspartate aminotransferase (AST), alanine aminotransferase (ALT), HBV DNA, albumin and total bilirubin levels from baseline in patients treated with ETV for at least 16 weeks. Patient demographics, disease information, drug administration reports, occurrence of AEs, and clinical laboratory evaluations were also collected. Changes in ALT levels for biochemical efficacy and HBV DNA levels for virological efficacy were assessed.

Clinical effectiveness data were collected and defined with a 5-level assessment tool (markedly improved, improved, no change, aggravated, and unassessable, compared with ‘baseline’) according to the physician’s assessment, based on ALT, HBV DNA levels and improvement of patient’s symptoms.
Kim CW, et al. Safety and effectiveness of entecavir

Statistical analysis
Data are expressed as mean ± standard deviation (SD) values, or as frequencies and percentages. Statistical analyses were performed using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA). Student t test, paired t test, Pearson chi-squared test, Fisher exact test, and logistic regression analyses were used where appropriate, and performed two-sided at the 5% significance level. Factors affecting safety and efficacy rates were identified by multivariate analysis using a logistic regression model.

Subgroup analysis
A post hoc subgroup analysis was carried out on data from 3,444 patients with or without cirrhosis, and duration of ETV therapy was examined. This subgroup was further divided based on medical history, value of baseline platelet count (≥ 100,000/mm³), or medical records on diagnosis of cirrhosis. Patients with unclear information about their cirrhosis status, or those that had never been treated with ETV were excluded from this analysis.

RESULTS
Baseline characteristics of study patients
The main baseline characteristics of patients studied for the safety evaluation are shown in Table 1. There were 2,375 male patients (70.56%) and 991 female patients (29.44%), with a mean ± SD age of 43.74 ± 11.41 years. The most populated group was the 40- to 49-year-old, which comprised 1,161 patients (34.49%), followed by the 30- to 39-year-old, comprising 840 patients (24.96%) and the 50- to 59-year-old with 683 patients (20.29%). There were also 20 pediatric patients (≥ 12 and ≤ 19 years old, 0.59%), and 139 elderly patients (> 65 years old, 4.13%).

Most of the study participants were outpatients (2,821 patients, 83.78%). There were 427 patients with a previ-
ous medical history (12.68%), and 476 patients (14.14%) had concurrent disease, which included 115 patients (3.42%) with renal disorders, 868 smokers (25.79%), 1,206 patients (35.82%) who were alcohol users, and 1,199 patients (35.46%) with cirrhosis versus 2,182 patients (64.54%) without cirrhosis.

**Other patient characteristics**

Mean period of disease, from diagnosed date to first treatment date with ETV, was 2.92 ± 4.38 years. The number of patients who had a family history of CHB (1,334 patients, 39.86%) and this was the most dominant group. The most common routes of infection were through perinatal infection (1,323 patients, 39.32%), contact with an infected person (627 patients, 18.63%), and through blood transfusions (17 patients, 0.51%).

A total of 736 patients (21.86%) were taking concomitant medications, the most common being alimentary tract and metabolism class of drugs, which were administered in 522 patients (70.92%). Other concurrent medications administered were for liver therapy and lipotropic, bile therapy, peptic ulcer and gastroesophageal reflux disease, as well as blood glucose lowering drugs. Cardiovascular medications were administered in 258 patients (35.05%).

**Summary of AEs**

Investigators recorded the occurrence of observed and patient-reported AEs for the safety assessment. Of the patients included in the safety evaluation (Table 2), 380 AEs were reported in 255 (7.57%) cases. Of these, 67 adverse drug reactions (ADR) were reported in 54 (1.60%) cases, which may have occurred due to causality with ETV. Unexpected AEs were 253 events in 188 cases (5.58%), and serious AEs (SAE) were 19 events in nine cases (0.27%). Serious adverse drug reactions (SADR) were three events

| Variable                  | No. of patients | No. of events | Rate (% of patients) |
|---------------------------|-----------------|---------------|----------------------|
| Adverse event             | 255             | 380           | 7.57                 |
| Adverse drug reaction     | 54              | 67            | 1.60                 |
| Serious adverse event     | 9               | 19            | 0.27                 |
| Serious adverse drug reaction | 2            | 3             | 0.06                 |
| Suspected unexpected serious adverse reaction | 2 | 3 | 0.06 |

**Table 1. Baseline characteristics of study subjects**

| Characteristic                  | Mean ± SD   | No. of patients (%) |
|--------------------------------|-------------|---------------------|
| Male sex                       | 2,375       | (70.56)             |
| Age, yr (range)                | 43.74 ± 11.41 (16 – 85) |             |
| Inpatient:outpatient           | 546 (16.22):2,821 (83.78) |             |
| Medical history (past)         | 427 (12.68) |                     |
| Concurrent disease             | 476 (14.14) |                     |
| Renal disorder                 | 115 (3.42)  |                     |
| Smoking                        | 868 (25.79) |                     |
| Alcohol consumption            | 1,206 (35.82)|                    |
| Liver cirrhosis                | 1,199 (35.46)|                    |
| Hepatitis B virus DNA, log10 copies/mL | 7.02 ± 1.76 | 2,696 |
| Alanine aminotransferase, U/L  | 177.93 ± 265.94 | 3,103 |
| Aspartate aminotransferase, U/L| 154.63 ± 217.52 | 3,101 |
| Entecavir therapy duration, day| 258.34 ± 151.49 | 3,359 |

*Defined as patients have experience with hospitalization more than once.

**Table 2. Summary of adverse events**

*Occurred in the same two patients.*
Table 3. Adverse events*a and adverse drug reactions

| Category                              | No. of cases (%) | No. of events | No. of cases (%) | No. of events |
|---------------------------------------|------------------|---------------|------------------|---------------|
| Gastrointestinal disorder             | 104 (3.09)       | 120           | 27 (0.8)         | 30            |
| Heartburn                             | 22 (0.65)        | 22            | 7 (0.21)         | 8             |
| Dyspepsia                             | 21 (0.62)        | 21            | 6 (0.18)         | 6             |
| Nausea                                | 14 (0.42)        | 15            | 4 (0.12)         | 4             |
| Upper abdominal pain                  | 10 (0.30)        | 10            | 8 (0.24)         | 8             |
| General disorder                      | 70 (2.08)        | 76            | 12 (0.36)        | 12            |
| Fatigue                               | 46 (1.37)        | 46            | 10 (0.3)         | 10            |
| Respiratory disorder                  | 40 (1.19)        | 51            | 0                | 0             |
| Common cold                           | 21 (0.62)        | 22            | 0                | 0             |
| Cough                                 | 8 (0.24)         | 8             | 0                | 0             |
| Central & peripheral nervous system disorder | 26 (0.77)   | 27            | 6 (0.18)         | 6             |
| Dizziness                             | 11 (0.33)        | 11            | 3 (0.09)         | 3             |
| Headache                              | 10 (0.3)         | 10            | 3 (0.09)         | 3             |
| Skin and appendages disorder          | 15 (0.45)        | 16            | 4 (0.12)         | 4             |
| Pruritus                               | 7 (0.21)         | 7             | 3 (0.09)         | 3             |
| Musculoskeletal disorder              | 14 (0.42)        | 15            | 0                | 0             |
| Urinary tract disorder                | 10 (0.3)         | 10            | 3 (0.09)         | 3             |
| Neoplasm                              | 9 (0.27)         | 10            | 0                | 0             |
| Hepatic neoplasm                      | 8 (0.24)         | 9             | 0                | 0             |
| Others                                | 100 (2.97)       | 171           | 0                | 0             |
| Total                                 | 255 (7.57)       | 378           | 53 (1.57)        | 65            |

*aAdverse events occurred in ≥ 0.2% of patients.

Table 4. Serious adverse events

| Adverse event                          | Severity | Action taken | Outcome   | Relationship |
|----------------------------------------|----------|--------------|-----------|--------------|
| Abdominal pain                         | Mild     | None         | Improved  | Probably not |
| Nasal septum deviation                 | NA       | NA           | Resolved  | Probably not |
| Sinusitis                              | NA       | NA           | Resolved  | Probably not |
| Eyelid skin disorder                   | NA       | NA           | NA        | NA           |
| Hepatic neoplasm                       | Severe   | None         | Unable to determine | Probably not |
| Hepatic neoplasm                       | Moderate | None         | No change | Probably not |
| Hepatic neoplasm                       | Severe   | None         | Improved  | Probably not |
| Hepatic neoplasm                       | Moderate | None         | Unable to determine | Probably not |
| Hepatic neoplasm                       | Severe   | None         | Resolved  | Probably not |
| Gastrointestinal hemorrhage            | Moderate | None         | Resolved  | Probably not |
| Gastric angiodysplasia                 | NA       | NA           | Resolved  | Unable to determine |
| Portal hypertension                    | NA       | NA           | Resolved  | Unable to determine |
| (portal hypertensive gastropathy)      | NA       | NA           | Resolved  | Unable to determine |
| Cholangitis                            | Severe   | None         | Aggravated| Probably not |
| Sepsis                                 | Severe   | None         | Aggravated| Probably not |
| Ascites                                | Moderate | None         | Improved  | Probably not |
| Ascites                                | Moderate | None         | Improved  | Probably not |
in two cases (0.06%), and unexpected SAE/SADR were three events in two cases (0.06%). SADRs were in the same patients. SADRs and suspected, unexpected, serious adverse reactions are also shown in Table 2, namely eyelid skin disorder, gastric angiodysplasia, and portal hypertensive gastropathy.

Looking at all the AEs over this study (Table 3), regardless of the causal relationship with ETV therapy, gastrointestinal disorders were the most frequent (3.09%, 104 cases with 120 events). For those cases where a specific event was reported, the most common events were heartburn (0.65%, 22 events), dyspepsia (0.62%, 21 events), nausea (0.42%, 15 events), and upper abdominal pain (0.30%, 10 events) (Fig. 2).

Unexpected AEs and ADRs associated with the gastrointestinal system, such as heartburn (0.65%, 23 events) and upper abdominal pain (0.30%, 10 events) were commonly observed.

SAEs are shown in Table 4. The severity of SAEs reported ranged from mild to severe, and action taken with ETV therapy was ‘none’ in most SAEs.

### Predictive factors by multivariate analysis

Logistic regression analyses were performed to identify the factors that were suspected to have influenced the reported 380 AEs in 255 patients. For the safety analysis, the incidence of AEs was classified as the dependent variable while several factors derived from the case report forms were considered as independent variables, including gender, age, in/outpatient, medical history, concurrent disease, smoking, alcoholic history, family history, severity prior medication, daily dose, treatment duration, total treatment dose, concomitant medication, and renal disease (Table 5). The multivariate analysis (Table 5) revealed that gender, in/outpatient, medical history, family history, treatment duration, total treatment dose, and concomitant medication had influenced incidence rates for the reported AEs. Specifically, an AE was less likely to occur in males (odds ratio [OR], 0.61; 95% confidence interval [CI], 0.45 to 0.83; \( p = 0.002 \)), patients undergoing long treatment durations (OR, 0.68; 95% CI, 0.53 to 0.88; \( p = 0.003 \)), and more likely to occur in inpatients (OR, 1.77; 95% CI, 1.28 to 2.44; \( p = 0.001 \)), patients with a medical history (OR, 1.94; 95% CI, 1.39 to 2.70; \( p < 0.000 \)), patients with a family history of disease (OR, 1.33; 95% CI, 1.00 to 1.76; \( p = 0.047 \)), patients receiving > 115 mg treatment dose in total (OR, 1.46; 95% CI, 1.02 to 2.09; \( p = 0.038 \)), and patients receiving concomitant medications (OR, 3.84; 95% CI, 2.81 to 5.24; \( p < 0.000 \)).

Similarly, the logistic regression analysis was conducted with efficacy as the dependent variable and independent variables from the patient case reports (Table 6). The analysis revealed that prior antiviral medication was the only risk factor contributing to poor efficacy for ETV therapy and, therefore, therapy was more effective in patients without prior antiviral medication (OR, 0.44; 95% CI, 0.27 to 0.71; \( p = 0.001 \)).

### Efficacy and clinical effectiveness evaluation

Table 7 shows the change in AST, ALT, HBV DNA, albumin, and total bilirubin before and after ETV treatment. Mean ALT levels before and after ETV treatment were 177.93 ± 265.94 and 34.71 ± 60.38 IU/L, respectively, and mean decrease in ALT was 143.21 ± 274.09 IU/L (\( p < 0.000 \)). Mean AST before and after treatment were 154.63 ± 217.52 and 32.85 ± 24.54 IU/L, respectively, and mean decrease in AST was 121.78 ± 219.68 IU/L (\( p < 0.000 \)). Mean HBV DNA before and after treatment were 7.02 ± 1.76 and 3.79 ± 1.79 log\(_{10}\) copies/mL, respectively, and mean decrease in HBV DNA was 3.23 ± 1.92 log\(_{10}\) copies/mL (\( p < 0.000 \)). Mean albumin before and after ETV treatment were 4.07 ± 0.57 and 4.22 ± 0.49 g/dL, respectively, and mean increase in albumin was 0.16 ± 0.44 g/dL (\( p < 0.000 \)).

| Table 4. Continued |
|-------------------|
| Adverse event \(^a\) | Severity | Action taken | Outcome | Relationship |
|-------------------|
| Hemoperitoneum     | Moderate | None         | Improved| Probably not |
| Hemoperitoneum     | Moderate | None         | Improved| Probably not |
| Hepatic encephalopathy | Severe  | None         | Resolved| Probably not |
| NA, not available. |
| \(^a\)Based on the World Health Organization Adverse Reactions Terminology criteria. |
Mean total bilirubin before and after ETV treatment were 1.28 ± 1.55 and 0.98 ± 0.68 mg/dL, respectively, and mean decrease in total bilirubin was 0.30 ± 1.52 mg/dL (p < 0.000). Although the mean treatment duration was relatively short, but 258 days, these laboratory parameters were improved significantly.

We also analysed the overall clinical effectiveness rate and efficacy-related factors regarding cases that were

Table 5. Factors associated with occurrence of adverse events (logistic regression)

| Factor                               | Estimate | SE   | OR   | 95% CI       | p value |
|--------------------------------------|----------|------|------|--------------|---------|
| Sex (male vs. female)                | −0.50    | 0.16 | 0.61 | 0.45–0.83    | 0.002   |
| Age, yr                              | 0.00     | 0.01 | 1.00 | 0.98–1.01    | 0.628   |
| Patient type (inpatient vs. outpatient) | 0.57    | 0.16 | 1.77 | 1.28–2.44    | 0.001   |
| Medical history (yes vs. no)         | 0.66     | 0.17 | 1.94 | 1.39–2.70    | < 0.000 |
| Concurrent disease (yes vs. no)      | 0.25     | 0.19 | 1.28 | 0.88–1.86    | 0.192   |
| Smoker (yes vs. no)                  | −0.25    | 0.19 | 0.78 | 0.54–1.33    | 0.188   |
| Alcohol use (yes vs. no)             | 0.27     | 0.17 | 1.32 | 0.95–1.83    | 0.100   |
| Family history (yes vs. no)          | 0.29     | 0.14 | 1.33 | 1.00–1.76    | 0.047   |
| Severity                             | 0.04     | 0.11 | 1.04 | 0.84–1.30    | 0.706   |
| Prior medications (yes vs. no)       | 0.07     | 0.17 | 1.07 | 0.77–1.49    | 0.691   |
| Daily dose, mg (> 0.5 vs. ≤ 0.5)     | −0.34    | 0.24 | 0.71 | 0.44–1.15    | 0.164   |
| Treatment duration, wk (> 24 vs. ≤ 24) | −0.38  | 0.13 | 0.68 | 0.53–0.88    | 0.003   |
| Total treatment dose, mg (> 115 vs. ≤ 115) | 0.38  | 0.18 | 1.46 | 1.02–2.09    | 0.038   |
| Concomitant medicine (yes vs. no)    | 1.34     | 0.16 | 3.84 | 2.81–5.24    | < 0.000 |
| Renal disease (yes vs. no)           | −0.57    | 0.39 | 0.57 | 0.26–1.21    | 0.144   |

SE, standard error; OR, odds ratio; CI, confidence interval.

\(^a^p < 0.005.

Table 6. Factors associated with entecavir efficacy (logistic regression)

| Factor                               | Estimate | SE   | OR   | 95% CI       | p value |
|--------------------------------------|----------|------|------|--------------|---------|
| Sex (male vs. female)                | −0.51    | 0.27 | 0.60 | 0.36–1.01    | 0.056   |
| Age, yr                              | −0.01    | 0.01 | 0.99 | 0.97–1.01    | 0.180   |
| Patient type (inpatient vs. outpatient) | 0.42    | 0.31 | 1.52 | 0.83–2.79    | 0.178   |
| Medical history (yes vs. no)         | −0.19    | 0.28 | 0.83 | 0.48–1.45    | 0.513   |
| Concurrent disease (yes vs. no)      | 0.24     | 0.36 | 1.27 | 0.63–2.57    | 0.498   |
| Smoker (yes vs. no)                  | 0.17     | 0.26 | 1.19 | 0.72–1.97    | 0.495   |
| Alcohol use (yes vs. no)             | −0.11    | 0.23 | 0.90 | 0.57–1.40    | 0.629   |
| Family history (yes vs. no)          | 0.24     | 0.21 | 1.27 | 0.84–1.94    | 0.257   |
| Severity                             | −0.27    | 0.16 | 0.76 | 0.56–1.05    | 0.092   |
| Prior medications (yes vs. no)       | −0.82    | 0.25 | 0.44 | 0.27–0.71    | 0.001   |
| Daily dose, mg (> 0.5 vs. ≤ 0.5)     | −0.50    | 0.29 | 0.60 | 0.34–1.07    | 0.083   |
| Treatment duration, wk (> 24 vs. ≤ 24) | −0.33  | 0.27 | 0.72 | 0.43–1.22    | 0.223   |
| Total treatment dose, mg (> 115 vs. ≤ 115) | 0.28  | 0.27 | 1.32 | 0.78–2.26    | 0.303   |
| Concomitant medicine (yes vs. no)    | −0.32    | 0.25 | 0.72 | 0.44–1.18    | 0.193   |
| Renal disease (yes vs. no)           | −0.81    | 0.49 | 0.45 | 0.17–1.17    | 0.101   |

SE, standard error; OR, odds ratio; CI, confidence interval.

\(^a^p < 0.005.

https://doi.org/10.3904/kjim.2016.111

www.kjim.org
‘markedly improved’ and ‘improved’ (Table 8). Of the 3,367 patients evaluated for safety, 3,115 were also evaluated for efficacy and clinical effectiveness (238 patients treated < 16 weeks and a further 14 patients for whom efficacy or effectiveness could not be assessed were excluded). Of these, the number of patients evaluated as ‘markedly improved’ and ‘improved’ were 1,449 (46.52%) and 1,558 (50.02%), respectively. A further 87 patients (2.79%) were evaluated as having ‘no change,’ and 21 patients (0.67%) were evaluated as ‘aggravated.’ Therefore, overall clinical effectiveness rate, which was assessed by physician who took care of patients, based on ALT, HBV DNA and improvement of symptoms, was 96.53% (3,007/3,115 patients).

Table 7. Efficacy evaluation: changes in laboratory test markers related to hepatitis

| Variable                      | No.   | Baseline     | Follow-up    | Difference      | p value     |
|-------------------------------|-------|--------------|--------------|----------------|-------------|
| Albumin                       | 2,329 | 4.07 ± 0.57  | 4.22 ± 0.49  | 0.16 ± 0.44    | < 0.000     |
| Total bilirubin               | 2,533 | 1.28 ± 1.55  | 0.98 ± 0.68  | –0.30 ± 1.52   | < 0.000     |
| Alanine aminotransferase      | 3,103 | 177.93 ± 265.94 | 34.71 ± 60.38 | –143.21 ± 274.09 | < 0.000     |
| Aspartate aminotransferase    | 3,101 | 154.63 ± 217.52 | 32.85 ± 24.54 | –121.78 ± 210.68 | < 0.000     |
| Hepatitis B virus DNAa         | 2,696 | 7.02 ± 1.76  | 3.79 ± 1.79  | –3.23 ± 1.92   | < 0.000     |

Values are presented as mean ± SD. Paired t test was used for statistical analysis.
a Log10 copies/mL.

Table 8. Overall efficacy evaluation assessed by physician

| Category               | No. (%)     |
|------------------------|-------------|
| Markedly improved      | 1,449 (46.52) |
| Improved               | 1,558 (50.02) |
| No change              | 87 (2.79)   |
| Aggravated             | 21 (0.67)   |
| Efficacy cases         | 3,007 (96.53) |
| No efficacy cases      | 108 (3.47)  |

Table 9. Subgroup analysis: serious adverse eventsa by cirrhosis status

| Serious adverse event | Cirrhosis | Non-cirrhosis | p value |
|-----------------------|-----------|---------------|---------|
| No                    | 1,193 (99.50) | 2,181 (99.95) | 0.010   |
| Yes                   | 6 (0.50)   | 1 (0.05)      |         |

Pearson chi-square test and Fisher exact test were used for statistical analyses.
a Excludes 63 patients with missing information.

Subgroup analysis

The analysis showed that 35.46% of patients had cirrhosis, and that AEs were more common in these patients than in cirrhosis-free patients. AEs in both groups were those more commonly associated with the gastrointestinal system. In total, AEs were reported in 104 patients with cirrhosis (8.67%), and 142 patients without cirrhosis (6.51%, p = 0.020).

SAEs were 10 events in six patients with cirrhosis (0.50%), and five events in one patient without cirrhosis (0.05%) (Table 9). Due to missing information for two patients, data could not be analysed for four events that were reported for those two patients. There was a significant difference in the rates of SAEs in patients with cirrhosis compared with those without (p = 0.010). A higher rate of serious hepatic AEs (regardless of causality) has been observed in patients with liver cirrhosis.

DISCUSSION

The safety profile of ETV in phase III studies involving more than 1,000 patients has been established to be generally well tolerated [8-10]. Carcinogenesis has been observed in animal models exposed to very high doses of ETV [11], giving rise to an ongoing study of clinical outcomes in more than 12,500 patients with CHB receiving long-term ETV versus other antiviral agents [12,13]. However, to date, there is no evidence for the occurrence of cancers as a result of ETV treatment in patients. Mitochondrial toxicity has been raised as a potential concern associated with nucleos(t)ides, as they can inhibit the mitochondrial polymerase-gamma, causing mitochondrial DNA depletion and subsequent mitochondrial toxicity. However, ETV has a low potential for interfering with the mitochondrial polymerase-gamma [14].

98 www.kjim.org
consequence of mitochondrial toxicity can be lactic acidosis, which appears to be observed more frequently in patients with decompensated disease. ETV is well tolerated in patients with decompensated cirrhosis; findings from this surveillance did not reveal occurrence of lactic acidosis, consistent with previously published clinical trial data, as well as several other reports of Korean, Chinese, and EU patient cohorts in real-world settings [13,15-17].

The incidence rate of AEs over the surveillance period was 7.57%, and the rate of ADRs (which cannot rule out occurrence due to a causal relationship with the treatment) was 1.60%. Unlike clinical trials, which are conducted under standardized conditions and with strict safety monitoring, some limitation abound in a real clinical practice setting in terms of collection of safety data, thus limiting direct comparisons. When comparing with AE profiles reported in a clinical trial comprising more than 1,000 subjects (ETV 0.5 or 1 mg), upper respiratory infection, headache and nasopharyngitis were commonly reported AEs, regardless of the causality with ETV treatment [18]. In this surveillance, gastrointestinal disorders were reported as the most common AEs, including upper abdominal pain, heartburn, dyspepsia, and nausea. ADRs were infrequent, and reported for myalgia and neuropathy-related AEs in comparison clinical trials, whilst gastrointestinal disorders were the most common AEs reported in our surveillance.

When evaluating baseline predictive factors of safety outcomes by logistic regression analysis, we found that gender, inpatients, medical history, family history, and concomitant medication were associated with incidence of AEs. Considering that most of the concomitant medications were anti-inflammatory drugs and most AEs were gastrointestinal symptoms, it is surmised that the incidence rate of AEs is likely to be influenced by various factors related to concomitant medications, rather than directly to ETV therapy.

In addition, it is considered that the general health of inpatients and patients with a medical history or on concomitant medications might be weaker than that of outpatients, and patients without a medical history or on concomitant medications. Therefore, factors related to the general health condition of patients could not be excluded for the analysis on incidence rates of AEs.

Our results indicate that gender and family histo-
genotype C is the most prevalent genotype in Korea and patients were most likely infected with HBV genotype C [4]. Finally, there was no control arm to compare safety profiles, or analyze any causal relationship between emerging AEs and relevant influencing factors, or ETV treatment. Despite these limitations, the strength of this study is that it provides reference data for safety events that can occur in nation-wide real practice for a large number of heterogeneous CHB patients, over a 6-year period. A number of real-world studies comprising large numbers of CHB patients have recently been published, but most have focused on efficacy or resistance profiles, not safety profiles. Real-world studies provide valuable information about treatments in clinical practice, as they include patient populations usually under-represented in clinical studies and, thus, can identify rare or late-emerging AEs. In this respect, our surveillance has the unique feature of conducting both safety and efficacy analyses for ETV treatment, based on nation-wide routine clinical practice in Korea.

In addition, we evaluated clinical effectiveness which means improvements of not only laboratory parameters such as ALT and HBV DNA but also patient’s subjective well-being sense and symptoms. This effectiveness of ETV was assessed by physician who took care of patients, with a 5-level assessment tool (markedly improved, improved, no change, aggravated, and unassessable, compared with baseline). Clinical effectiveness is important in real practice because it includes improvement of patient’s symptoms as well as ALT and HBV DNA. More than 95% of patients with ETV therapy assessed as marked improved or improved state compared to baseline in our nation-wide surveillance study.

In summary, this large-scale nation-wide surveillance study confirmed that ETV is well tolerated and clinically effective in Korean patients with CHB in a real-world setting.

2. Regardless of the causality with entecavir therapy, ‘gastrointestinal system disorder’ including heartburn, dyspepsia, nausea, and upper abdominal pain was most common adverse event.

3. Concomitant medication was high risk factor influencing adverse event incidence rates of patients under entecavir therapy so, patients with concomitant medicines should be closely monitored.

**KEY MESSAGE**

1. Entecavir is well tolerated and clinically effective in Korean patients with chronic hepatitis B in a real-world setting.

**Conflicts of interest**

This surveillance was sponsored by Bristol-Myers Squibb Korea. Kyungha Yu and Cyril Llamaso are employees of Bristol-Myers Squibb. Others are no conflict of interest relevant to this article.

**Acknowledgments**

We thank all 132 institutions and co-investigators who actively participated to this study.

**REFERENCES**

1. World Health Organization (WHO). Hepatitis B [Internet]. Geneva: WHO, c2017 [cited 2017 Sep 5]. Available from: http://www.who.int/mediacentre/factsheets/fs204/en/index.html.

2. Chae HB, Kim JH, Kim JK, Yim HJ. Current status of liver diseases in Korea: hepatitis B. Korean J Hepatol 2009;15 Suppl 6:S13-S24.

3. Korea Centers for Disease Control & Prevention. Korea National Health and Nutrition Examination Survey [Internet]. Cheongju (KR): Korea Centers for Disease Control & Prevention, c2012 [cited 2017 Sep 5]. Available from: http://knhanes.cdc.go.kr/knhanes/index.do.

4. Bae SH, Yoon SK, Jang JW, et al. Hepatitis B virus genotype C prevails among chronic carriers of the virus in Korea. J Korean Med Sci 2005;20:816-820.

5. Kim H, Jee YM, Song BC, et al. Molecular epidemiology of hepatitis B virus (HBV) genotypes and serotypes in patients with chronic HBV infection in Korea. Intervirology 2007;50:52-57.

6. Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of chronic hepatitis B.
7. Pol S, Lampertico P. First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings: from clinical trials to clinical practice. J Viral Hepat 2012;19:377-386.

8. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-1010.

9. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-1020.

10. Sherman M, Yurdaydın C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006;130:2039-2049.

11. Bristol-Myers Squibb Company. Entecavir (BMS-200475): Antiviral Drugs Advisory Committee (AVDAC) briefing document [Internet]. Silver Spring (MD): Food and Drug Administration, 2005 [cited 2017 Sep 5]. Available from: https://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4094B1_01_BristolMyersSquibb-entecavir.pdf.

12. National Institutes of Health (NIH). Study of entecavir in patients with chronic hepatitis B virus infection [Internet]. Bethesda (MD): NIH, c2015 [cited 2017 Sep 5]. Available from: http://clinicaltrials.gov/ct2/show/NCT00388674.

13. Hou JL, Jia JD, Wei L, et al. Efficacy and safety of entecavir treatment in a heterogeneous CHB population from a ‘real-world’ clinical practice setting in China. J Viral Hepat 2013;20:811-820.

14. Mazzucco CE, Hamatake RK, Colonno RJ, Tenney DJ. Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition. Antimicrob Agents Chemother 2008;52:598-605.

15. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology 2011;54:491-100.

16. Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010;52:176-182.

17. Zoutendijk R, Reijnders JG, Brown A, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. Hepatology 2011;54:443-451.

18. Manns MP, Akarca US, Chang TT, et al. Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901. Expert Opin Drug Saf 2012;11:361-368.

19. Tenney DJ, Pokornowski KA, Rose RE, et al. Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients. J Hepatol 2009;50(Suppl 1):S10.

20. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009;49:1503-1514.